Other

Norgine Bv

Aurigene Oncology Limited

Olema Pharmaceuticals, Inc.

Jubilant Biosys Limited

Jubilant Prodell LLC

Chandregowda Venkateshappa

Rajagopal Bakthavatchalam

Sridharan Rajagopal

Dhanalakshmi Sivanandhan

Susanta Samajdar

David C Myles

Bheemashankar A Kulkarni

Raghava Reddy Kethiri

Athisayamani Jeyaraj Duraiswamy

Rohit Saxena

Rajendra Kristam

Reena Chawla

David Yeghikyan

Kalisankar Bera

Rama Kishore V P Putta

Muralidhar Pendyala

Jeyaraj D A

Suraj Tatyasaheb Gore

Raymond A Ng

Mohd Zainuddin

Rajenda Kristam

Akila Parvathy Dharshinis

Vellarkad Viswanathan

Juluri Suresh

Sarkis Barret Kalindjian

Sanjay Venkatachalapathi Kadnur

Christopher Alexander Hewson

Ajit Kumar Behera

Manas Kumar Basu

Sanjeev Giri

Vellarkad Narayana Viswanadhan

The present disclosure describes acylsulfonamide compounds of Formula (J), and pharmaceutically acceptable salts, compositions, methods, and uses thereof. Such compounds are believed to be therapeutically useful as KAT6A inhibitors particularly in the treatment and/or prevention of diseases and disorders mediated by KAT6A in a subject.

Acylsulfonamide KAT6A inhibitors

The compounds of Formula Ib, Formula Ia, and Formula I are described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The process of preparation of the compounds of Formula Ib, Formula Ia, and Formula I is also described. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are 2-(benzyloxy)pyrimidine derivatives that are inhibitors of PD-1/PD-L1 activation. 

Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation

The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation. 

Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation

The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders mediated by epidermal growth factor receptor (EGFR) family kinases. 

Substituted pyrimidine compounds, compositions and medicinal applications thereof

The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD). 

Compounds useful as CCR9 modulators

Growing community of inventors

Bengaluru, India

Chandregowda Venkateshappa